Pioneering JDRF researcher Professor Roman Hovorka today launches the world’s first licensed, downloadable artificial pancreas app for people with type 1 diabetes.
The commercial launch is a milestone in the journey towards full artificial pancreas technology for everyone with type 1 diabetes.
The CamAPS FX app works with an insulin pump and a glucose monitor to automatically deliver insulin to people with the condition via a complex algorithm.
Relieving the burden
Currently, people with type 1 diabetes rely on a routine of finger-prick blood tests and insulin injections or infusions just to stay alive, because their pancreas no longer produces insulin itself.
The app – which Professor Hovorka hopes will become available in the future on the NHS – will take over much of the management of the condition. This is particularly important at night, when many people with type 1 diabetes experience potentially dangerous low blood glucose levels.
The app can also upload the user’s blood glucose measurements seamlessly to Diasend, an online platform, enabling their diabetes team to provide more personalised care.
Backed by research
The CamAPS FX app is backed by 13 years of clinical research carried out by Professor Hovorka and his research group, and funded by JDRF, Diabetes UK, the National Institute for Health Research, the National Institutes of Health, Horizon 2020, and The Leona M and Harry B Helmsley Charitable Trust.
It is licensed for use by both adults and children with the condition – including pregnant women, and children aged one and up.
It is the first artificial pancreas system to be licensed for use in pregnancy, or by young children.
CamAPS FX is now available for UK users to download onto Android phones via the Amazon Appstore.
The app is available on a subscription basis starting at £70 per month.
At launch, the artificial pancreas app will be supported by a small number of UK diabetes clinics. People who wish to use the app will need to confirm which clinic they attend, and must be using a Dana RS pump and a Dexcom G6 continuous glucose monitor.
But Professor Hovorka and his research team will work to continue to bring this technology to all who need it, via the NHS. Key to this will be the generation of data to support the case for NHS provision.
Next steps for the artificial pancreas
The CamAPS FX app is a first step towards a fully automated and interoperable artificial pancreas.
Fully automated and interoperable artificial pancreas technology will fundamentally change life with type 1 diabetes, by working with a range of insulin pumps and glucose monitors to lift the burden of managing a condition that is relentlessly unpredictable day and night.
Professor Hovorka will continue refining the artificial pancreas through research into mealtime glucose control and improving ease of use.
Professor Hovorka, Professor of Metabolic Technology at the University of Cambridge, said:
“This is a major stepping stone towards providing widely available, clinically proven, and user friendly artificial pancreas technology to people with type 1 diabetes.
“Our aim is to alleviate the ever-present burden of type 1 diabetes and improve health outcomes. This is the outcome of hard work, with more to come. We are indebted to all who are helping us on this journey.”
Karen Addington, UK Chief Executive of JDRF, said:
“JDRF is proud to have supported Professor Hovorka’s artificial pancreas research from the beginning, nearly 15 years ago. This app is a major innovation and a significant milestone on the road to a fully automated and interoperable artificial pancreas.
“There’s still more work to do, but this is an exciting step.”
Fiona O’Reilly, who has been using the app as part of a clinical trial, said:
“Overall, it makes me feel free. It is the closest I have been to living without the burden of type 1 diabetes since I was diagnosed, which is a fabulous feeling. I feel less fearful of hypoglycaemia, and less ashamed of the fact that I find achieving good glycaemic control so tricky.
“And it makes me feel more positive of my future with diabetes, that I have a chance of avoiding all the associated complications. It also makes me feel lucky to live in a time where this technology is possible and really grateful to have had the chance to try it out.”